Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

Journal of Experimental Medicine

Volumn 202, Issue 11, 2005, Pages 1507-1516

  Liu, Kang ^a   Idoyaga, Juliana ^b   Charalambous, Anna ^a   Fujii, Shin Ichiro ^a   Bonito, Anthony ^a   Mordoh, Jose ^b   Wainstok, Rosa ^b   Bai, Xue Feng ^c   Liu, Yang ^c   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALPHA CD40 ANTIBODY; ALPHA GALACTOSYLCERAMIDE; ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOLIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FEMALE; IRRADIATION; LYMPH NODE; LYMPHOID ORGAN; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR RESISTANCE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GAMMA RAYS; IMMUNOTHERAPY, ACTIVE; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLASMACYTOMA; SPLEEN;

EID: 28544431840     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20050956     Document Type: Article

References (61)

1. Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-778.
2. Mumberg, D., M. Wick, and H. Schreiber. 1996. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin. Immunol. 8:289-293.
3. Rakhmilevich, A.L., R.J. North, and E.S. Dye. 1993. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer. 55:338-343.
4. Townsend, S.E., F.W. Su, J.M. Atherton, and J.P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477-6483.
5. Katsanis, E., M.A. Bausero, A. Panoskaltsis-Mortari, B.B. Dancisak, Z. Xu, P.J. Orchard, C.G. Davis, and B.R. Blazar. 1996. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-γ reduces their capacity to induce systemic immunity. Cancer Gene Ther. 3:75-82.
6. + T cell immunity against B16 melanoma. J. Immunol. 171:5940-5947.
7. Wang, M., V. Bronte, P.W. Chen, L. Gritz, D. Panicali, S.A. Rosenberg, and N.P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685-4692.
8. Moore, M.W., F.R. Carbone, and M.J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:777-785.
9. Morgan, D.J., H.T.C. Kreuwel, S. Fleck, H.I. Levitsky, D.M. Pardoll, and L.A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643-651.
10. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA. 95:1178-1183.
11. Dohring, C., L. Angman, G. Spagnoli, and A. Lanzavecchia. 1994. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer. 57:1-6.
12. Liu, X., J.X. Gao, J. Wen, L. Yin, O. Li, T. Zuo, T.F. Gajewski, Y.X. Fu, P. Zheng, and Y. Liu. 2003. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197:1721-1730.
13. + T lymphocytes in vivo. J. Exp. Med. 194:1339-1348.
14. Tamada, K., K. Shimozaki, A.I. Chapoval, G. Zhu, G. Sica, D. Flies, T. Boone, H. Hsu, Y.X. Fu, S. Nagata, et al. 2000. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6:283-289.
15. Bai, X.F., J.X. Gao, J. Liu, J. Wen, P. Zheng, and Y. Liu. 2001. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res. 61:6860-6867.
16. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713-716.
17. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217-1224.
18. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820-7825.
19. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M.J. Brunda, M.P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049-1058.
20. Dunussi-Joannopoulos, K., K. Runyon, J. Erickson, R.G. Schaub, R.G. Hawley, and J.P. Leonard. 1999. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood. 94:4263-4273.
21. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophate colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
22. Soiffer, R., T. Lynch, M. Mihm, K. Jung, C. Rhuda, J.C. Schmollinger, F.S. Hodi, L. Liebster, P. Lam, S. Mentzer, et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 95:13141-13146.
23. Rodolfo, M., C. Zilocchi, B. Cappetti, G. Parmiani, C. Melani, and M.P. Colombo. 1999. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Ther. 6:865-872.
24. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:86-89.
25. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, et al. 1998. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. J. Exp. Med. 188:2163-2173.
26. Liu, K., T. Iyoda, M. Saternus, K. Kimura, K. Inaba, and R.M. Steinman. 2002. Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196:1091-1097.
27. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289-1302.
28. + CTL to cause tumor eradication. J. Immunol. 173:6753-6759.
29. + T cells. J. Exp. Med. 197:985-995.
30. Huang, A.Y.C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965.
31. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200:297-306.
32. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J. Exp. Med. 198:267-279.
33. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171:5140-5147.
34. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-1128.
35. Van Den Broeke, L.T., E. Daschbach, E.K. Thomas, G. Andringa, and J.A. Berzofsky. 2003. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171:5842-5852.
36. Fujii, S., K. Shimizu, M. Kronenberg, and R.M. Steinman. 2002. Prolonged interferon-γ producing NKT response induced with α- galactosylceramide-loaded dendritic cells. Nat. Immunol. 3:867-874.
37. Mocikat, R., H. Braumuller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch, A. Bubeck, J. Louis, R. Mailhammer, G. Riethmuller, et al. 2003. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 19:561-569.
38. Van den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373-1384.
39. Sarma, S., Y. Guo, Y. Guilloux, C. Lee, X.F. Bai, and Y. Liu. 1999. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J. Exp. Med. 189:811-820.
40. Guilloux, Y., X.F. Bai, X. Liu, P. Zheng, and Y. Liu. 2001. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res. 61:1107-1112.
41. Zheng, P., Y. Guo, Q. Niu, D.E. Levy, J.A. Dyck, S. Lu, L.A. Sheiman, and Y. Liu. 1998. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature. 396:373-376.
42. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 278:1626-1629.
43. Fujii, S., K. Liu, C. Smith, A.J. Bonito, and R.M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199:1607-1618.
44. Garrett, W.S., L.M. Chen, R. Kroschewski, M. Ebersold, S. Turley, S. Trombetta, J.E. Galan, and I. Mellman. 2000. Developmental control of endocytosis in dendritic cells by Cdc42. Cell. 102:325-334.
45. α14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
46. + T cells in vivo. Proc. Natl. Acad. Sci. USA. 91:3077-3081.
47. Ray, P.K., T.B. Poduval, and K. Sundaram. 1977. Antitumor immunity, V.BCG-induced growth inhibition of murine tumors. Effect of hydrocortisone, antiserum against theta antigen, and γ-irradiated BCG. J. Natl. Cancer Inst. 58:763-767.
48. Dye, E.S., R.J. North, and C.D. Mills. 1981. Mechanisms of antitumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J. Exp. Med. 154:609-620.
49. Woodruff, M.F., and J.L. Boak. 1966. Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts. Br. J. Cancer. 20:345-355.
50. Sinniah, D., J.C. White, A. Omar, and C.P. Chua. 1978. Acute leukemia in Malaysian children. Cancer. 42:1970-1975.
51. Gillessen, S., Y.N. Naumov, E.E. Nieuwenhuis, M.A. Exley, F.S. Lee, N. Mach, A.D. Luster, R.S. Blumberg, M. Taniguchi, S.P. Balk, et al. 2003. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. USA. 100:8874-8879.
52. Giaccone, G., C.J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B.M. von Blomberg, R.J. Scheper, H.J. van der Vliet, A.J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α- galactosylceramide (KRN7000) in patients with solid tumors. Clin. Canc. Res. 8:3702-3709.
53. Granucci, F., C. Vizzardelli, E. Virzi, M. Rescigno, and P. Ricciardi-Castagnoli. 2001. Transcriptional reprogramming of dendritic cells by differentiation stimuli. Eur. J. Immunol. 31:2539-2546.
54. Huang, Q., D. Liu, P. Majewski, L.C. Schulte, J.M. Korn, R.A. Young, E.S. Lander, and N. Hacohen. 2001. The plasticity of dendritic cell responses to pathogens and their components. Science. 294:870-875.
55. Inaba, K., M. Pack, M. Inaba, H. Sakuta, F. Isdell, and R.M. Steinman. 1997. High levels of a major histocompatibility complex II - self peptide complex on dendritic cells from lymph node. J. Exp. Med. 186:665-672.
56. Wu, D.Y., N.H. Segal, S. Sidobre, M. Kronenberg, and P.B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:173-181.
57. Ferrone, S., and F.M. Marincola. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 16:487-494.
58. Schmieg, J., G. Yang, R.W. Franck, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198:1631-1641.
59. Wu, D., G.W. Xing, M.A. Poles, A. Horowitz, Y. Kinjo, B. Sullivan, V. Bodmer-Narkevitch, O. Plettenburg, M. Kronenberg, M. Tsuji, et al. 2005. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. USA. 102:1351-1356.
60. Berendt, M.J., and R.J. North. 1980. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151:69-80.
61. North, R.J. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res. 45:1-43.